STOCKHOLM, Feb. 21, 2022 /PRNewswire/ — Implantica AG (publ), an rising and quick rising med-tech corporation that is pioneering ground breaking methods to address continual health situations with wise implants, currently announces that it has concluded an considerable eHealth patent filing that exceeded 25,000 web pages, the culmination of a entire year’s work of Implantica’s team and patent lawyers. The filing encompasses 59 new patent purposes focused on Implantica’s eHealth platform and a wide assortment of apps.
This complete submitting signifies a appreciable strengthening and term-extension of Implantica’s patent defense. The patent applications will present fundamental coverage for the eHealth system in general and increase the scope and term of the patent safety for the pipeline goods. This landmark submitting will – in the years to appear – be divided into many hundred specific patent apps, constructing patent defense for the system and the pipeline products and solutions as the advancement progresses. The most significant eHealth application comprised 1,950 web pages and consisted of 596 web pages of drawings, which is around 100-fold the dimension of a standard patent. For the duration of 2021, Implantica validated 824 issued patents in complete in a variety of nations.
“Implantica has designed its eHealth platform to be in the forefront of the eHealth revolution with the probability to transform procedure on distance therefore conserving charges for culture. With this amazing one particular-year patent perform, we will have the chance to preserve that eHealth advantage in the marketplace or license technology to other firms. This kind of systematic and state-of-the-art patent perform builds the basis of a productive prolonged-term enterprise. We are creating the platform for an amazing company prospective heading ahead and modifying the procedure landscape for clients,” said Peter Forsell, CEO of Implantica.
For more information, remember to get hold of:
Nicole Pehrsson, Trader Relations
Telephone (CH): +41 ()79 335 09 49
Implantica is listed on Nasdaq Very first North Leading Development Sector in Stockholm.
The firm’s Licensed Adviser is FNCA Sweden AB, +46 ()8 528 00 399, [email protected]
The info was despatched for publication, by way of the agency of the make contact with person set out higher than, on February 21, 2022 at 08:00 a.m. CET.
Implantica is a medtech enterprise focused to bringing state-of-the-art know-how into the physique. Implantica’s direct solution, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will most likely generate a paradigm change in anti-reflux remedy as supported by thriving scientific demo results. Implantica also focuses on eHealth within the system and has produced a wide, patent protected, item pipeline centered partly on two platform technologies: an eHealth system created to check a broad variety of well being parameters, handle remedy from within the human body and communicate to the caregiver on length and a wi-fi energising system built to electrical power remote controlled implants wirelessly as a result of intact pores and skin. Implantica is detailed on Nasdaq Initial North Leading Advancement Marketplace (ticker: IMP A SDB).
Stop by www.implantica.com for even further details.
This info was brought to you by Cision http://news.cision.com
The adhering to information are accessible for download: